Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

The National Health Care Institute carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line treatment of chronic lymphatic leukaemia (CLL) in patients without del(17p) or TP53 mutation.
The National Health Care Institute’s advice is to only (additionally) include ibrutinib in the insured package for the subgroup of patients for whom it complies with ‘established medical science and medical practice’: older, less fit patients with CLL without del(17p) or TP53 mutation for whom the use of anti-CD20 is contraindicated or has more disadvantages for the patient than advantages.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.